Abstract:The diagnosis of Myelodysplastic syndromes (MDS) is frequently challenging, especially in terms of the distinction from the other non-neoplastic causes of cytopenia. Currently, it is based on the presence of peripheral blood cytopenias, peripheral blood and bone marrow dysplasia/blasts, and clonal cytogenetic abnormalities, but MDS diagnostic features are polymorphic and non-specific. We investigated the utility of complete blood count (CBC) and research parameters (RUO) from the analyzer BC 6800 Plus (Mindray Diagnostics) to discriminate MDS-related cytopenia. Methods: 100 samples from healthy individuals were used to establish the values of research parameters in normal subjects. A retrospective study was conducted including 66 patients diagnosed with MDS, 90 cytopenic patients due to other diseases (cancer patients receiving therapy, aplastic anemia, other hematological malignancies) and 50 with macrocytic anemia. The Wilcoxon test was applied to detect statistical differences among the groups of patients, considering p < 0.05 significant. The diagnostic performance of the RUO parameters for discriminating MDS among cytopenias was evaluated using receiver operating characteristic (ROC) curve analysis. Amultivariable logistic regression model was performed to identify the potential predictors for having MDS. The area under curve (AUC) and the Hosmer–Lemeshow test of the model were assessed. The performance of the model was verified in a prospective study including 224 cytopenic patients (validation group). Results: In the MDS group, the mean cell volume (MCV), percentage of macrocytic red cells (MAC), red cell distribution width (RDW) and immature platelets fraction (IPF) had increased values compared to the cytopenic and normal patients, while platelets, red and white cell counts, Neu X (related to the cytoplasmic complexity of neutrophils), Neu Y (related to nucleic acid content) and Neu Z (related to cell size) were lower (p 0.80; MAC, RDW and IPF AUC > 0.76. The multivariable model demonstrated that Neu X and Neu Y could be used in the recognition of MDS, AUC 0.88. In the validation group, 89.0% of the MDS patients were well classified. Conclusion: MDS are common malignant disorders with a poor prognosis, and early diagnosis is warranted for optimal benefit from treatment. RUO gain insights to detect dysplasia of MDS and could be used in the differential diagnosis of MDS from cytopenias of other etiologies.

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve This paper aims to explore the application value of Complete Blood Count (CBC) and Research Use Only parameters (RUO) in diagnosing Myelodysplastic Syndromes (MDS). ### Main Findings - **Challenges in Diagnosing MDS**: Diagnosing MDS is challenging, especially in distinguishing it from other non-neoplastic cytopenias. Current diagnosis is based on peripheral blood cytopenia, dysplasia/blasts in peripheral blood and bone marrow, and clonal chromosomal abnormalities, but these features are not specific. - **Research Methods**: Through retrospective and prospective studies, CBC and RUO parameters of MDS patients were compared with those of patients with cytopenias due to other causes. The study used the Mindray BC-6800 Plus analyzer, including data from 100 healthy individuals, 66 MDS patients, 90 patients with cytopenias due to other causes, and 50 patients with megaloblastic anemia. - **Statistical Analysis**: The Wilcoxon test was used to detect statistical differences between groups, and the Receiver Operating Characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of RUO parameters in distinguishing MDS from other cytopenias. - **Main Results**: - In the MDS group, Mean Cell Volume (MCV), Macrocyte Percentage (MAC), Red Cell Distribution Width (RDW), and Immature Platelet Fraction (IPF) were significantly higher than in normal and cytopenia patients. - Neutrophil Complexity (Neu X), Fluorescence Intensity (Neu Y), and Size (Neu Z) were significantly lower in MDS patients. - Multivariate logistic regression models showed that Neu X and Neu Y could be used to identify MDS, with an AUC value of 0.88. - In the validation group, 81.8% of MDS patients and 82.8% of non-MDS cytopenia patients were correctly classified. ### Conclusion The study indicates that RUO parameters can provide valuable clues to help detect dysplastic features of MDS and may be used to distinguish MDS from cytopenias due to other causes. Although there are differences in RUO parameters provided by analyzers from different manufacturers, the findings of this study offer new insights for routine laboratories in diagnosing MDS.

Complete Blood Counts and Research Parameters in the Detection of Myelodysplastic Syndromes